RANKL/RANK-beyond bones (Q28308042)

Europe PubMed Central

title

RANKL/RANK-beyond bones (English)

0 references

Josef M Penninger

5

0 references

Toshikatsu Hanada

2

object named as

Toshikatsu Hanada

0 references

Verena Sigl

3

object named as

Verena Sigl

0 references

Daniel Schramek

4

object named as

Daniel Schramek

0 references

author name string

Reiko Hanada

Journal of Molecular Medicine

1

0 references

language of work or name

English

0 references

publication date

July 2011

0 references

published in

0 references

volume

89

0 references

issue

7

0 references

page(s)

647-56

0 references

cites work

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

RANK is essential for osteoclast and lymph node development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Reaching a genetic and molecular understanding of skeletal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

RANK-L and RANK: T cells, bone loss, and mammalian evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Bone versus immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Osteoimmunology: interplay between the immune system and bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Positive and negative selection of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

A central role for central tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Regulation of mammary gland development by tissue interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

The genetic transformation of bone biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Therapeutic approaches to bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Genetic regulation of osteoclast development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

GATA-3 and the regulation of the mammary luminal cell fate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Transcriptional regulators in mammary gland development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Breast cancer metastasis: markers and models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

The RANK/RANKL/OPG triad in cancer-induced bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Control of mammary stem cell function by steroid hormone signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Progesterone induces adult mammary stem cell expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Estrogen-progestin replacement therapy and endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

The role of fever in the infected host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Mechanisms of CNS response to systemic immune challenge: the febrile response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Central control of thermogenesis in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Cytokines and fever. Mechanisms and sites of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Central control of fever and female body temperature by RANKL/RANK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Cytokines, PGE2 and endotoxic fever: a re-assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

The role of exercise and PGC1alpha in inflammation and chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0749-Z

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

12 December 2020

Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer

1 reference

12 December 2020

Heritable disorders of the RANKL/OPG/RANK signaling pathway

1 reference

12 December 2020

1 reference

12 December 2020

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

12 December 2020

Cytokine-induced sickness behavior: mechanisms and implications

1 reference

12 December 2020

Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis

1 reference

12 December 2020

Side-branching in the mammary gland: the progesterone-Wnt connection.

1 reference

12 December 2020